Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGGS18 + ZG005 in advanced solid tumors
NCT06938880Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of ZGGS18, nilvanstomig in Cervical Cancer (CC), hepatocellular carcinoma (HCC), neuroendocrine tumors (NETs), lung cancer, sponsored by Zelgen. Started May 2025; status: recruiting.
02
Drugs
ZGGS18nilvanstomig
03
Conditions
Cervical Cancer (CC)hepatocellular carcinoma (HCC)neuroendocrine tumors (NETs)lung cancer
Beyond the preview
Go deeper on NCT06938880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06938880.